June 20, 2024

Infertility Drugs Market Size to Worth USD 6.73 Bn By 2033

The global infertility drugs market size is expected to increase USD 6.73 billion by 2033 from USD 3.71 billion in 2023 with a CAGR of 6.13% between 2024 and 2033.

Key Points

  • The global infertility drugs market size accounted for USD 1.45 billion in 2023 and is expected to rise around USD 2.65 billion by 2033.
  • North America dominated the market with the largest market share of 39% in 2023.
  • Asia Pacific is expected to expand at the fastest CAGR of 6.93% during the forecast period.
  • By drug class, the gonadotropins segment has contributed more than 41% of market share in 2023.
  • By the drug class, the selective estrogen receptor modulators segment is predicted to show rapid growth in the market.
  • By the distribution channel, the hospital pharmacy segment has generated more than 55% of market share in 2023.
  • By distribution channel, the online pharmacy segment is expected to grow at a high rate over the forecast period.
  • By end-user, the women segment has contributed more than 74% of market share in 2023.
  • By end-user, the men segment will be the fastest-growing segment during the forecast period.

Infertility Drugs Market Size 2024 to 2033

The global infertility drugs market encompasses pharmaceutical products designed to treat infertility issues in both men and women. Infertility affects a significant population worldwide, driven by factors such as age-related fertility decline, lifestyle changes, and rising incidence of conditions like polycystic ovary syndrome (PCOS). This market is characterized by ongoing research and development aimed at introducing novel therapies and improving existing treatments to address the diverse causes of infertility.

Get a Sample: https://www.precedenceresearch.com/sample/4243

Growth Factors

The infertility drugs market is poised for growth due to several factors. Increasing awareness about fertility treatments, coupled with rising acceptance of assisted reproductive technologies (ART), is expanding the patient pool seeking medical intervention for infertility. Moreover, advancements in reproductive medicine, including the development of more effective and targeted drugs, are enhancing treatment outcomes. Additionally, the trend of delaying parenthood in developed regions is driving demand for fertility treatments, thereby boosting market growth.

Region Insights

Regional dynamics play a crucial role in the infertility drugs market. Developed regions like North America and Europe have well-established healthcare infrastructure and higher healthcare expenditure, facilitating greater adoption of infertility treatments. In contrast, emerging economies in Asia-Pacific and Latin America are witnessing rapid market growth due to improving access to healthcare services and increasing disposable income. Cultural attitudes towards family planning and fertility treatments also influence market trends across different regions.

Infertility Drugs Market Scope

Report CoverageDetails
Growth Rate from 2024 to 2033CAGR of 6.13%
Global Market Size in 2023USD 3.71 Billion
Global Market Size in 2024USD 3.94 Billion
Global Market Size by 2033USD 6.73 Billion
Largest MarketNorth America
Base Year2023
Forecast Period2024 to 2033
Segments CoveredBy Drug Class, By Distribution Channel, and By End-user
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Infertility Drugs Market Dynamics

Drivers

Key drivers fueling the growth of the infertility drugs market include the increasing prevalence of lifestyle-related factors impacting fertility, such as obesity and stress. Additionally, advancements in assisted reproductive technologies, including in vitro fertilization (IVF) and intrauterine insemination (IUI), are creating demand for complementary drug therapies. Furthermore, supportive government initiatives and insurance coverage for fertility treatments in some regions are facilitating market expansion.

Opportunities

The market presents opportunities for pharmaceutical companies to innovate and develop more efficacious and patient-friendly infertility drugs. Targeted therapies addressing specific causes of infertility, such as hormonal imbalances or ovulatory disorders, hold promise for market penetration. Furthermore, expanding market outreach to underserved regions and improving affordability of treatments can unlock new growth opportunities within the infertility drugs market.

Challenges

Despite growth prospects, the infertility drugs market faces challenges such as regulatory complexities and varying reimbursement policies across different regions. Safety concerns associated with certain infertility drugs also pose challenges to market adoption. Additionally, the high cost of fertility treatments and limited insurance coverage in some regions may restrict market accessibility, particularly for economically disadvantaged populations.

Read Also: Calcium Peroxide Market Size to Worth USD 3.38 Bn By 2033

Infertility Drugs Market Recent Developments

  • In February 2024, Lupin, a major global pharma company, launched Ganirelix Acetate Injection. It is a single-dose prefilled syringe indicated for inhibiting premature luteinizing hormone (LH) surges in women who undergo ovarian hyperstimulation.
  • In March 2024, Future Generali India Insurance launched ‘Health PowHER’, a product designed exclusively for women healthcare at various stages of their lives. There will be varios treatments offered by the product, and one of the treatments will be infertility treatment. This will include oocyte cryopreservation, stem cell storage, wellness programme, insurance for newborn defects, nursing care, and many more benefits.

Infertility Drugs Market Companies

  • Merck & Co., Inc.
  • Ferring B.V.
  • Organon Group of Companies
  • Abbott
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Mankind Pharma
  • Teva Pharmaceutical Industries LTD.
  • Sanofi

Segments Covered in the Report

By Drug Class

  • Gonadotropins
  • Aromatase Inhibitors
  • Selective Estrogen Receptor Modulators (SERMs)
  • Dopamine Agonists
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Specialty & Retail Pharmacy
  • Online Pharmacy

By End-user

  • Men
  • Women

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/